Spero Therapeutics, Inc. (SPRO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.20. The rating moved from Neutral to Oversold on August 13, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$1.20
• Last changeMoved from Neutral to Oversold on August 13, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Spero Therapeutics is a small, clinical-stage biotech with limited near-term visibility on revenues and an elevated need for external funding. The combination of binary pipeline risk, likely cash burn, and thin liquidity makes the equity vulnerable to dilution and downside from any clinical or financing news. Broader sector tailwinds around biologics manufacturing and diagnostics do not materially de-risk Spero absent clear clinical progress or a strategic partnership. Near-term scenarios favor downside absent a near-term positive catalyst or demonstrable funding solution; monitoring cash runway, upcoming clinical readouts, and any partnership announcements will be critical for reassessing the outlook.

Key factors

• Small-cap biotech profile with limited public information and no recent material EDGAR updates provided in the brief
• High cash-burn profile typical of clinical-stage biotechs; likely need for near-term financing or partnership to sustain operations
• Pipeline uncertainty and binary clinical/regulatory outcomes that can produce large share-price moves
• Low liquidity and thin trading typical at sub-$5 equity prices, amplifying downside on negative news
• Macro and sector environment is cautiously optimistic for growth, but current sector themes (CDMO/biologics demand) may not directly benefit Spero's near-term commercial prospects
• Absence of clear commercial revenue or established market share reduces near-term upside

Risks

• Failure or delay in clinical development or regulatory setbacks for lead programs
• Dilutive equity financings or debt issuance that materially reduce existing shareholder value
• Weak liquidity leading to exaggerated volatility and difficulty executing large trades
• Competitive threats from better-funded peers or alternative therapies
• Reimbursement, pricing pressure, or payer rationalization that could limit future commercialization potential
• Negative investor sentiment or loss of key partnerships that would further constrain funding and operations

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.